Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme

OBJECTIVE: Increased risk of serious adverse events (AEs) was reported for tofacitinib relative to tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis (RA) aged ≥50 years enriched for cardiovascular (CV) risk (ORAL Surveillance). We assessed post hoc the potential risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy, Curtis, Jeffrey R, Charles-Schoeman, Christina, Mysler, Eduardo, Yamaoka, Kunihiro, Richez, Christophe, Palac, Hannah, Dilley, Deanne, Liu, Jianzhong, Strengholt, Sander, Burmester, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423494/
https://www.ncbi.nlm.nih.gov/pubmed/37308218
http://dx.doi.org/10.1136/ard-2023-223916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423494/
https://www.ncbi.nlm.nih.gov/pubmed/37308218
http://dx.doi.org/10.1136/ard-2023-223916

Ejemplares similares